BRIEF-Bristol-Myers Squibb says Health Canada approved Daklinza in combination with Sofosbuvir

Tue May 24, 2016 7:30am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

May 24 (Reuters) - Bristol-myers Squibb Co

* Myers squibb announces health canada's approval of daklinza in combination with sofosbuvir

* Says health canada's approval of daklinza in treatment of chronic hepatitis c in adult patients Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)